Cost modeling for alternate routes of administration of opioids for cancer pain.
The economic considerations relative to neuraxial infusion can be looked at with different types of economic models, including cost-minimization, cost-effectiveness, and cost-benefit analyses. A theoretical predictive model was developed about 2 years ago using a computer spreadsheet and based on four levels of supportive data. The model shows that the breakeven point at which it becomes less expensive to administer opioids with an intrathecal/implanted pump, rather than an epidural/external pump, is between 3 and 6 months after the start of pain management. In addition, the break even point between systemic treatment and spinal delivery with an implanted system is between 1 1/2 and 2 1/2 years from start of pain treatment.
Hassenbusch
S J
SJ
Department of Neurosurgery, M. D. Anderson Cancer Center, Houston, Texas, USA.
D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000627:therapeutic use; D001416:Back Pain / Q000188:drug therapy / Q000191:economics; D003362:Cost-Benefit Analysis; D004333:Drug Administration Routes; D016503:Drug Delivery Systems / Q000191:economics*; D006801:Humans; D007278:Injections, Spinal / Q000191:economics; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics; D010146:Pain / Q000188:drug therapy* / Q000191:economics; D019736:Prostheses and Implants / Q000191:economics
D000701:Analgesics, Opioid